UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 71.26% | 46.23% | 29.72% | -40.87% | -49.51% |
| Total Depreciation and Amortization | 12.08% | 31.19% | 121.90% | 140.23% | 126.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -204.88% | -- |
| Total Other Non-Cash Items | 22.69% | 96.67% | -45.08% | 31.71% | -41.92% |
| Change in Net Operating Assets | -568.95% | -1,063.19% | -209.87% | -54.73% | 89.72% |
| Cash from Operations | 17.12% | -7.83% | -181.41% | -52.80% | -67.70% |
| Capital Expenditure | 57.45% | -22.73% | 85.22% | 9.38% | -67.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -93.93% | 20.39% | -54.34% | 129.52% | 136.28% |
| Cash from Investing | -94.11% | 20.32% | -54.28% | 129.41% | 136.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202.73% | 426.47% | 46,623.94% | -45.28% | -99.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -99.98% |
| Cash from Financing | 68.92% | 191,676.47% | 44,007.04% | -79.11% | -99.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.20% | 98.82% | -56.01% | 97.26% | -112.56% |